TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05167578

Intervention type: BEHAVIORAL
Intervention: Medication reconciliation
Description: A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
Study: NCT04725032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
Study: NCT04900818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ033721 (givastomig)
Description: Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ033721 (givastomig) , nivolumab, chemotherapy
Description: Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
Study: NCT04670523

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early postoperative day 0 (POD 0) chest tube removal.
Description: Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
Description: Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
Study: NCT06549218

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: newborn genetic screening and whole genome sequencing
Description: newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
Study: NCT05988528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifuroxazide
Description: Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
Study: NCT05879926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian Function Suppression + Aromatase Inhibitor
Description: Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian Function Suppression + Aromatase Inhibitor
Description: Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy + Ovarian Function Suppression
Description: Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Study: NCT04957368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen + Midazolam
Description: Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
Study: NCT05160376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help CBT with email reminder and text message
Description: An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help CBT with email reminder and text message
Description: An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback calls on participants' progress
Description: Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
Study: NCT06000254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High energy density pulse electromagnetic field
Description: The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physiotherapy
Description: Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham High energy density pulse electromagnetic field
Description: The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
Study: NCT04807192

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: one administration of SBRT 8 Gy at D1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: one administration of SBRT 8 Gy at D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: 4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
Study: NCT05894096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma Jet Treatment
Description: Application of Colf Atmospheric Plasma Jet on the wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alginate Patch
Description: Application of Alginate Patches on the wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alginate Patch
Description: Application of Alginate Patches on the wound
Study: NCT05614362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Channa Striatus extract
Description: Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin given three-times-daily for each patient
Study: NCT05447364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: 1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: 2 tabs of Pregabalin Brillior 75 mg
Study: NCT04725032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
Study: NCT05664776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic office chair
Description: The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic office chair
Description: The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
Study: NCT04381845

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID19 immunization testing
Description: serological COVID19 test with confirmation at J15 during hospitalization
Study: NCT06338592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyLungHealth
Description: MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyLungHealth
Description: MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DecisionPrecision+
Description: DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DecisionPrecision+
Description: DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
Study: NCT05462028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration training
Description: The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vibration training
Description: The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ergometer exercise
Description: ergometer exercise training
Study: NCT06222086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise training with telerehabilitation
Description: The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
Study: NCT05462028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ergometer exercise
Description: ergometer exercise training
Study: NCT04733417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
Study: NCT05462028

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ergometer exercise
Description: ergometer exercise training
Study: NCT05638685

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
Study: NCT05210166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tSCS and Lokomat
Description: A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tSCS and Lokomat
Description: The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
Study: NCT05826782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Proxeed Plus 2*1 A arm
Description: Proxeed plus 2 x daily sachets (2\*1) three mounths

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 x daily sachets (2\*1) three mounths
Study: NCT04733417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib
Description: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
Study: NCT04917536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Humeral neailling in humeral fractures
Description: Humeral neailling in humeral fractures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Humeral neailling in humeral fractures
Description: Humeral neailling in humeral fractures
Study: NCT05248672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812
Description: Study Drug
Study: NCT06431139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSPIRE intervention protocol
Description: 2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
Study: NCT03770663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and azathioprine
Description: European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
Study: NCT05248672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812
Description: Study Drug
Study: NCT04896606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients will receive standard of care for COVID-19.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive standard of care for COVID-19.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV2-CTLS
Description: Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
Study: NCT06501612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor and Undermyfork App
Description: Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
Study: NCT04884009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701； Famitinib
Description: SHR-1701+ Famitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR-1701
Study: NCT05894187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animated video
Description: Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
Study: NCT05978063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 2.0 mg tablets
Description: Oral difelikefalin 2.0 mg administered twice daily
Study: NCT06501612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
Study: NCT06577415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAY1225
Description: Administered SC
Study: NCT06493240

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 45 Gy radiation dose in 25 fractions to the pelvis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: 200mg Sintilimab after radiation (3 times, 2-week interval)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: TME surgery for 6\~8 weeks after radiation